Tag Archives: ALK

Linux

Count and print the number of occurences

Leave a comment

By arch

I have some files as shown below

GLL ALK 654-656 654 656
SEM LYG 655-657 655 657
SEM LYG 655-657 655 657
ALM ARN 656-658 656 658
ALM ARN 656-658 656 658
ALM ARN 656-658 656 658
LEG LEG 658-660 658 660
LEG LEG 658-660 658 660

The value of GLL is 654. Th value of ALK is 656. In the same way, 4th column represents the values of first column. 5th column represents the values of second column.

I tried the following program to count the occurrences of each number in the fourth and fifth column.

for i in folder1/*.pdb;
do
awk ‘
BEGIN {
path=sprintf(“%s”, “/home/arch/Desktop/folder2/”)
}
!s[1″:”$4″:”$5]++{sU[$4]++;tot++}
!s[2″:”$4″:”$5]++{sU[$5]++;tot++}
END {
sub(/.*//,””,FILENAME)
for (x in sU)
print x, sU[x], sU[$1] > path FILENAME;
}’ $i;
done

The above program prints as follows

660 1
654 1
655 1
656 2
657 1
658 2

But I would like to get the output as follows

660 LEG 1
654 GLL 1
655 SEM 1
656 ALM 2
657 LYG 1
658 LEG 2

your suggestions would be appreciated!!

…read more

Source: FULL ARTICLE at The UNIX and Linux Forums

Business, Finance, Occupation & Industry

Synta Announces Presentations at the 2013 Annual Meeting of the American Association of Cancer Resea

Leave a comment

By Business Wirevia The Motley Fool

Filed under:

Synta Announces Presentations at the 2013 Annual Meeting of the American Association of Cancer Research

LEXINGTON, Mass.–(BUSINESS WIRE)– Synta Pharmaceuticals Corp. (NAS: SNTA) announced today that poster presentations related to studies with ganetespib, a selective Hsp90 inhibitor in clinical development by the company, will be presented at the 2013 Annual Meeting of the American Association of Cancer Research in Washington, D.C. Presentations include:

Inhibition of mTOR enhances the activity of HSP90 inhibitors in part through cessation of heat shock protein synthesis

Presentation: Sunday, April 7, 1:00 – 5:00 PM ET
Abstract number: 1038
Authors: He, et al.

Ultra-deep sequencing of circulating free DNA to identify predictive, mutated HSP90 clients in the GALAXY Trial (NCT01348126): a randomized phase IIB/III study of ganetespib (STA-9090) in combination with docetaxel versus docetaxel alone in subjects with stage IIIb/IV NSCLC

Presentation: Monday, April 8, 1:00 – 5:00 PM ET
Abstract number: 2012
Authors: Fennell, et al.

The importance of dose schedule with HSP90 inhibitors: Results from a Phase II study in dogs with mast cell tumors

Presentation: Tuesday, April 9, 8:00 AM – 12:00 PM ET
Abstract number: 3369
Authors: London, et al.

Differential sensitivities to heat shock protein 90 (HSP90) inhibitors in anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) cells

Presentation: Tuesday, April 9, 8:00 AM – 12:00 PM ET
Abstract number: 3272
Authors: Lee, et al.

Heat shock protein 90 functional inhibition regulates epithelial to mesenchymal transformation, invasion and migration via NF-kB and HIF-1α signaling in colorectal cancer

Presentation: Tuesday, April 9, 8:00 AM – 12:00 PM ET
Abstract number: 2707
Authors: Ganji, et al.

About Ganetespib

Ganetespib is an inhibitor of heat shock protein 90 (Hsp90) that is structurally unrelated to first-generation, ansamycin-related Hsp90 inhibitors. In preclinical experiments, ganetespib has shown activity in multiple tumor models …read more

Source: FULL ARTICLE at DailyFinance

Business, Finance, Occupation & Industry

ARIAD Announces Presentations of Preclinical Data at American Association for Cancer Research Annual

Leave a comment

By Business Wirevia The Motley Fool

Filed under:

ARIAD Announces Presentations of Preclinical Data at American Association for Cancer Research Annual Meeting

CAMBRIDGE, Mass.–(BUSINESS WIRE)– ARIAD Pharmaceuticals, Inc. (NAS: ARIA) today announced its schedule of preclinical data presentations to be made at the American Association for Cancer Research (AACR) Annual Meeting 2013, taking place Saturday, April 6 through Wednesday, April 10, 2013, in Washington.

Listed below are the details of presentations at AACR that describe ARIAD’s product candidates. There will be four presentations of data on ARIAD‘s targeted therapies, Iclusig™ (ponatinib) and AP26113; and one invited talk:

Title: Ponatinib is a highly potent inhibitor of activated variants of RET found in MTC and NSCLC
Date & Time: Monday, April 8, 1:00-5:00 p.m. (Poster)
Abstract: #2084
Location: Hall A-C, Poster Section 38

Title: Ponatinib potently inhibits the activity of mutant variants of FGFR commonly found in endometrial, lung and other cancers
Date & Time: Monday, April 8, 1:00-5:00 p.m. (Poster)
Abstract: #2083
Location: Hall A-C, Poster Section 38

Title: Ponatinib, a pan-BCR-ABL inhibitor, potently inhibits key activating and drug-resistant KIT mutants found in GIST
Date & Time: Tuesday, April 9, 8:00 a.m.-12:00 p.m. (Poster)
Abstract: #3394
Location: Hall A-C, Poster Section 42

Title: Design and development of ponatinib, a pan-BCR-ABL inhibitor for CML
Date & Time: Tuesday, April 9, 9:30-10:00 a.m. (Major symposium)
Presentation: #SY19-04
Location: Salon A-B, East Hall

Title: AP26113 possesses pan-inhibitory activity versus crizotinib-resistant ALK mutants and oncogenic ROS1 fusions
Date & Time: Wednesday, April 10, 8:00 a.m.-12:00 p.m. (Poster)
Abstract: #5655
Location: Hall A-C, Poster Section 42

About ARIAD

ARIAD Pharmaceuticals, Inc., headquartered in Cambridge, Massachusetts and Lausanne, Switzerland, is an integrated global oncology company focused on transforming the lives of cancer patients with breakthrough medicines. ARIAD is working on new medicines to advance the treatment of various forms of chronic and acute leukemia, lung cancer and other difficult-to-treat cancers. ARIAD utilizes computational and structural approaches to design small-molecule drugs that overcome resistance to existing cancer medicines. For additional information, visit http://www.ariad.com or follow ARIAD on Twitter (@ARIADPharm).

ARIAD
For Investors<br …read more
Source: FULL ARTICLE at DailyFinance

Business, Finance, Occupation & Industry

IWO, ALK, ATHN, CVLT: ETF Outflow Alert

Leave a comment

By ETFChannel.com

Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares Russell 2000 Growth Index Fund (AMEX: IWO) where we have detected an approximate $36.2 million dollar outflow — that’s a 0.8% decrease week over week (from 43,150,000 to 42,800,000). Among the largest underlying components of IWO, in trading today Alaska Air Group, Inc. (NYSE: ALK) is up about 2.8%, Athenahealth Inc (NASD: ATHN) is trading flat, and CommVault Systems Inc (NASD: CVLT) is higher by about 1%. For a complete list of holdings, visit the IWO Holdings page » …read more
Source: FULL ARTICLE at Forbes Markets